[EN] COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES [FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES À MÉDIATION PAR KIT ET PDGFRA
[EN] COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES [FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES MÉDIÉES PAR KIT ET PDGFRA
[EN] PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINE POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR KIT ET PDGFRA
申请人:BLUEPRINT MEDICINES CORP
公开号:WO2020210293A1
公开(公告)日:2020-10-15
The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and/or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
[EN] COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE MALADIES À MÉDIATION PAR KIT ET PDGFRA
申请人:BLUEPRINT MEDICINES CORP
公开号:WO2022081627A1
公开(公告)日:2022-04-21
The present disclosure provides compounds of Formula (I-0), pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFRα and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant ΚIT and PDGFRα. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
Compositions and methods for treating KIT- and PDGFRA-mediated diseases
申请人:Blueprint Medicines Corporation
公开号:US10829493B2
公开(公告)日:2020-11-10
The present disclosure provides compounds of Formula I,
pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFRα and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRα. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.
本公开提供了式 I 的化合物、
其药用盐和/或前述任一化合物的溶解物,这些化合物可用于治疗与突变KIT和PDGFRα相关的疾病和病症,并且在治疗与突变KIT和PDGFRα相关的疾病和病症时具有非脑穿透性的优势。本公开还提供了治疗胃肠道间质瘤和系统性肥大细胞增多症的方法。
PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
申请人:Blueprint Medicines Corporation
公开号:EP3953357A1
公开(公告)日:2022-02-16
COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES
申请人:Blueprint Medicines Corporation
公开号:US20200325141A1
公开(公告)日:2020-10-15
The present disclosure provides compounds of Formula I,
pharmaceutical salts thereof, and/or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFRα and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRα. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.